Giles AI secures £750k in pre-seed funding to scale its healthcare artificial intelligence platform.
The pre-seed round was backed by Regulatory Scientific and Health Solutions and angel investors to support product development and team growth.
Giles AI provides an artificial intelligence platform designed to streamline workflows across clinical trials, medical research, and regulatory affairs. The conversational system connects organisations to global health data for real-time insights.
Giles AI has secured £750k in a pre-seed funding round backed by strategic investor Regulatory Scientific and Health Solutions alongside angel investors. The fresh capital will be directed towards product development, team expansion, and go-to-market initiatives.
The London-based business offers an artificial intelligence tool aimed at improving decision-making and efficiency within biopharma, clinical trials, and healthcare academia. Having recently established a collaboration with Google, the firm intends to use the funds to scale its operations across the healthcare sector.
The transaction was facilitated via the FounderCatalyst fundraising platform.
From the founder
"We founded Giles AI to dramatically accelerate clinical and medical research using secure, cutting-edge, conversational AI. The impact is transformative: a typical 10-year, $1.5bn drug or device development pipeline can be accelerated significantly – getting life-saving innovations to market faster than ever before. With our collaboration with Google, our recent £750K pre-seed raise gives us the runway to scale rapidly -FounderCatalyst were instrumental facilitating the raise, providing expert legal guidance and an incredibly efficient process that let us stay focused on building the future of medical research."
Rishi Wadhera
Co-founder & CEO at Giles AI
Use of funds
- 01Continue product development
- 02Grow the team
- 03Accelerate go-to-market